C53H83NO14
Neat
958.24
1062122-63-7; Everolimus EP Impurity B; QAQ4Q483BA; Everolimus-19-ene open ring; Everolimus EP Impurity B (Acid); (19E/Z)-seco-[4-O-(2-Hydroxyethyl)]Rapamycin; (S)-1-{2-[(2R, 3R, 6S)-2-Hydroxy-6-{(2S, 3E, 5E, 7E, 9S, 11R, 13R, 14R, 15E, 17R, 19E, 21R)-14-hydroxy-22-[(1S, 3R, 4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-2, 13-dimethoxy-3, 9, 11, 15, 17, 21-hexamethyl-12, 18-dioxodocosa-3, 5, 7, 15, 19-pentaen-1-yl}-3-methyltetrahydro-2H-pyran-2-yl]-2-oxoacetyl}piperidine-2-carboxylic acid; 2-Piperidinecarboxylic acid, 1-[2-oxo-2-[(2R, 3R, 6S)-tetrahydro-2-hydroxy-6-[(2S, 3E, 5E, 7E, 9S, 11R, 13R, 14R, 15E, 17R, 19E, 21R)-14-hydroxy-22-[(1S, 3R, 4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-2, 13-dimethoxy-3, 9, 11, 15, 17, 21-hexamethyl-12, 18-dioxo-3, 5, 7, 15, 19-docosapentaen-1-yl]-3-methyl-2H-pyran-2-yl]acetyl]- and (2S)-
(2S)-1-[2-[(2R, 3R, 6S)-2-hydroxy-6-[(2S, 3E, 5E, 7E, 9S, 11R, 13R, 14R, 15E, 17R, 19E, 21R)-14-hydroxy-22-[(1S, 3R, 4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-2, 13-dimethoxy-3, 9, 11, 15, 17, 21-hexamethyl-12, 18-dioxodocosa-3, 5, 7, 15 and 19-pentaenyl]-3-methyloxan-2-yl]-2-oxoacetyl]piperidine-2-carboxylic acid
InChI=1S/C53H83NO14/c1-33(16-12-11-13-17-35(3)45(64-8)32-41-22-20-39(7)53(63,68-41)50(59)51(60)54-25-15-14-18-42(54)52(61)62)28-37(5)47(57)49(66-10)48(58)38(6)30-36(4)43(56)23-19-34(2)29-40-21-24-44(67-27-26-55)46(31-40)65-9/h11-13,16-17,19,23,30,33-34,36-37,39-42,44-46,48-49,55,58,63H,14-15,18,20-22,24-29,31-32H2,1-10H3,(H,61,62)/b13-11+,16-12+,23-19+,35-17+,38-30+/t33-,34+,36-,37-,39-,40+,41+,42+,44-,45+,46-,48-,49+,53-/m1/s1